Recommended Treatment Plan for Hidradenitis Suppurativa
For mild disease (Hurley stage I), start with topical clindamycin 1% solution combined with antiseptic cleansers; for moderate disease (Hurley stage II), use combination clindamycin 300 mg + rifampin 300 mg twice daily for 8-12 weeks; for severe disease (Hurley stage III), initiate adalimumab (the only FDA-approved biologic) while using antibiotics as adjunctive therapy, with surgical intervention for definitive management of chronic lesions. 1
Lifestyle Modifications
Weight loss and smoking cessation are critical first-line interventions that should be implemented immediately upon diagnosis. 2 While evidence for specific clothing recommendations is limited, loose-fitting cotton clothing may reduce friction-related flares, which 16% of patients report as a trigger. 3
Regarding personal care products:
- Use antiseptic cleansers (chlorhexidine, benzoyl peroxide, or zinc pyrithione) based on expert consensus 1
- Evidence does not support avoiding deodorants or antiperspirants despite anecdotal reports 3
- Shaving and chemical depilatories show no clear association with disease worsening 3
Common pitfall: Insufficient evidence exists to recommend routine zinc or vitamin D supplementation despite some retrospective data showing benefit. 3
Topical and Intralesional Therapies
For Hurley stage I disease, topical clindamycin 1% solution is the only evidence-based topical antibiotic, demonstrating reduced pustules in a 12-week RCT, though it does not affect inflammatory nodules or abscesses. 1 Benzoyl peroxide should be added to reduce Staphylococcus aureus resistance development. 1
For acute flares:
- Intralesional triamcinolone 10 mg/mL (0.2-2.0 mL) provides rapid pain relief within 1 day and reduces erythema, edema, and suppuration 1
- Resorcinol 15% cream (keratolytic/antiseptic) reduces pain and abscess duration but causes frequent irritant dermatitis 1
Systemic Antibiotics
The antibiotic hierarchy based on evidence quality:
First-line (Moderate Disease):
Clindamycin 300 mg + rifampin 300 mg, both twice daily for 8-12 weeks, shows 71-93% response rates across 187 patients in systematic review. 1 This can be repeated intermittently as monotherapy in mild-to-moderate disease or as adjuvant in severe disease.
Second-line:
Tetracycline 500 mg twice daily demonstrated 30% reduction in abscesses, performing similarly to topical clindamycin. 1 However, doxycycline showed no independent benefit when combined with adalimumab in PIONEER studies. 1
Third-line (Bridge Therapy):
Moxifloxacin 400 mg daily + metronidazole 500 mg three times daily + rifampin 300 mg twice daily achieved complete responses in 6/6 Hurley stage I, 8/10 stage II, but only 2/12 stage III patients. 1 Critical caveat: Stop metronidazole at 6 weeks to avoid neurologic toxicity. This regimen is reserved as bridge to surgery or long-term therapy. 1
Important limitation: In advanced disease, antibiotics have lower response rates and increased recurrence, serving only an adjunctive role. 1
Biologic Therapy
Adalimumab is the only FDA-approved biologic for moderate-to-severe HS and should be initiated when antibiotics fail or for rapidly progressive disease. 2, 4 Recent expert consensus indicates that 81% of specialists prescribe antibiotics despite anticipating inadequate responses, and 77% support earlier biologic initiation in cases of persistent flares during antibiotic treatment. 5
Specific phenotypes warranting earlier biologic intervention:
- Rapidly progressing disease
- Extensive anatomical involvement
- Persistent flares during antibiotic therapy
- Significant comorbidities 5
Emerging evidence: Anti-IL-17A/A-F inhibitors are in clinical trials and may expand treatment options. 4, 6 JAK inhibitors, complement inhibitors, and IL-1 blockade are under investigation. 6
Surgical Options
Surgical intervention is essential for definitive management and should be considered adjunctive to medical therapy, particularly for refractory cases and scarring. 7
Acute Lesions:
Deroofing is superior to incision and drainage, with only 4-17% recurrence rates versus nearly 100% for simple drainage. 3 The technique involves probing abscesses/sinuses and removing overlying skin stepwise while leaving the base untreated, achieving 90% patient satisfaction. 3
Critical distinction: Incision and drainage provides only acute relief when other methods are unavailable and should be avoided when possible. 3 For large nonrecurrent abscesses, drainage can reduce inflammation before definitive surgery.
Chronic Lesions:
Wide excision and deroofing show equivalent effectiveness (approximately 24% recurrence) and are superior to drainage (100% recurrence). 3 Younger age and multiple operative sites increase recurrence risk. 3
CO₂ laser excision with marsupialization shows promise for chronic lesions. 3
Pain Management and Wound Care
Intralesional triamcinolone provides significant pain reduction within 24 hours for acute inflammatory lesions. 1 The algorithm should incorporate systematic pain assessment and management strategies, though specific protocols require individualization based on lesion burden and patient tolerance.
Treatment Algorithm by Hurley Stage
Hurley Stage I (mild):
- Antiseptic cleansers + topical clindamycin 1% with benzoyl peroxide
- If inadequate: Add tetracycline 500 mg twice daily
- Intralesional triamcinolone for acute flares
- Deroofing for persistent lesions
Hurley Stage II (moderate):
- Clindamycin 300 mg + rifampin 300 mg twice daily × 8-12 weeks
- If inadequate: Initiate adalimumab
- Surgical deroofing or excision for chronic lesions
- Continue topical therapies as adjunct
Hurley Stage III (severe):
- Adalimumab as primary therapy 1, 2
- Antibiotics (clindamycin/rifampin) as adjunctive therapy
- Consider triple antibiotic therapy (moxifloxacin/metronidazole/rifampin) as bridge
- Wide surgical excision for definitive management 3
- Medical optimization before surgery improves outcomes 8
Critical practice point: The 2019 North American guidelines mandate 10-12 weeks of antibiotics before biologics per licensing regulations 5, but 79% of experts favor short-term biologic therapy over antibiotics for early-stage HS with aggressive features. 5 This represents evolving practice patterns that may precede future guideline updates.